Use of the new dengue vaccine Qdenga in Germany For whom and when?

被引:0
|
作者
Kling, Kerstin [1 ]
Kuelper-Schiek, Wiebe [1 ]
机构
[1] Robert Koch Inst, Abt Infekt Epidemiol 3, Fachgebiet Impfpravent, Berlin, Germany
关键词
Disease transmission; infectious; Travellers; Vaccine effectiveness; Virologically confirmed dengue; Antibody-dependent enhancement; HEALTHY-CHILDREN; EFFICACY; PHASE-3; RISK;
D O I
10.1007/s00112-024-01946-4
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Infections with mosquito-borne pathogens are on the rise worldwide, with dengue virus (DENV) infections leading the way. In the last two decades the World Health Organization (WHO) has recorded a tenfold increase in dengue cases worldwide, with 5.2 million cases reported in 2019. Until now, travellers have only been able to protect themselves from mosquito bites by taking individual measures (repellents, wearing long clothing). Vector control measures in endemic areas (e.g., by reducing open water reservoirs) reduce the local reproduction and spread of mosquitos. Since spring 2023, a dengue vaccine is available in Germany that is approved for people aged 4 years and older. The Standing Committee on Vaccination (STIKO) at the Robert Koch Institute recommends its use for travellers before exposure in the endemic country if they have previously had a laboratory confirmed DENV infection. As it cannot be ruled out based on the currently available data that the vaccination may lead to an increased severity of infection in dengue-naive people, the STIKO does not currently recommend the vaccination for people who have not yet had a confirmed DENV infection.
引用
收藏
页码:418 / 425
页数:8
相关论文
共 50 条
  • [1] Einsatz des neuen Dengue-Impfstoffs Qdenga in DeutschlandFür wen und wann?Use of the new dengue vaccine Qdenga in GermanyFor whom and when?
    Kerstin Kling
    Wiebe Külper-Schiek
    Monatsschrift Kinderheilkunde, 2024, 172 (5) : 418 - 425
  • [3] First clinical experiences with the tetravalent live vaccine against dengue (Qdenga®) in travellers: a multicentric TravVacNet study in Germany
    Koepke, Clara
    Rothe, Camilla
    Zeder, Andreas
    Boecken, Gerhard
    Feldt, Torsten
    Janke, Christian
    Jordan, Sabine
    Koehler, Carsten
    Loebermann, Micha
    Mueller, Andreas
    Orth, Hans Martin
    Pruefer-Kraemer, Luise Marie
    Schaefer, Johannes
    Slesak, Gunther
    Stich, August
    Belard, Sabine
    Thul, Nico
    Becker, Soeren L.
    Schneitler, Sophie
    TravVacNet Grp
    JOURNAL OF TRAVEL MEDICINE, 2025, 32 (02)
  • [4] Qdenga®- A promising dengue fever vaccine; can it be recommended to non-immune travelers?
    Angelin, Martin
    Sjolin, Jan
    Kahn, Fredrik
    Hedberg, Anna Ljunghill
    Rosdahl, Anja
    Skorup, Paul
    Werner, Simon
    Woxenius, Susanne
    Askling, Helena H.
    TRAVEL MEDICINE AND INFECTIOUS DISEASE, 2023, 54
  • [5] The decision to use ECT: For whom? When?
    Fink, M
    MOOD DISORDERS: SYSTEMATIC MEDICATION MANAGEMENT, 1997, 25 : 203 - 214
  • [6] When, for whom and how to use sibutramine?
    Astrup, A
    Toubro, S
    INTERNATIONAL JOURNAL OF OBESITY, 2001, 25 (Suppl 4) : S2 - S7
  • [7] When, for whom and how to use sibutramine
    A Astrup
    S Toubro
    International Journal of Obesity, 2001, 25 : S2 - S7
  • [9] The new Butantan Dengue Vaccine
    Passi, Gouri Rao
    INDIAN PEDIATRICS, 2024, 61 (04) : 394 - 394
  • [10] Opening in Singen Dengue: First Vaccine Production Site in Germany
    Schweizer, Beate
    FLUGMEDIZIN TROPENMEDIZIN REISEMEDIZIN, 2019, 26 (06): : 287 - 287